Hanmi Pharm's Efinopegdutide gets Fast Track Designation from FDA

Its development partner MSD plans to feature oral presentation for phase 2a clinical trial results of new drug candidate of NASH

Hanmi Pharm's Efinopegdutide gets Fast Track Designation from FDA
Yoo-Rim Kim 1
2023-06-13 12:08:04 youforest@hankyung.com
Bio & Pharma

Merck, known as MSD outside the United States and Canada, announced on Monday that Efinopegdutide, a technology transferred from the South Korean pharmaceutical company Hanmi Pharmaceutical Co., was granted Fast Track Designation from the U.S. Food and Drug Administration (FDA) for the treatment of nonalcoholic steatohepatitis (NASH).

The fast-track designation is a process by which the FDA accelerates the review speed to provide early access to patients for important new drugs in critical areas, such as the treatment of severe diseases. Currently, there are no approved treatments for NASH.

Efinopegdutide is a dual-action agent that activates both the GLP-1 receptor, which helps with insulin secretion and appetite suppression, and the glucagon receptor, which increases energy metabolism. Hanmi Pharm transferred the technology for efinopegdutide to MSD in Aug. 2020.

MSD plans to orally present the results of phase 2a clinical trial of efinopegdutide, conducted on adult patients with nonalcoholic fatty liver disease, at the European Association for the Study of the Liver (EASL) in Vienna, Austria, from June 21 to 24.

"The phase 2a results of efinopegdutide, which will be unveiled at EASL, along with the FDA's fast-track designation, will expedite the commercialization of efinopegdutide," an Hanmi Pharm official said. 

Write to Yoo-Rim Kim at youforest@hankyung.com
#Hanmi Pharm #Merck #MSD #Food and Drug Administration #efinopegdutide #nonalcoholic steatohepatitis #NASH #European Association for the Study of the Liver #EASL

Hanmi Pharmaceutical reports record-high revenue in 2022

Hanmi Pharmaceutical reports record-high revenue in 2022

South Korea's Hanmi Pharmaceutical Co. last year saw record-high performance thanks to its self-developed drugs, surpassing its previous best year of 2015, when half of sales came from technology export fees for new drug candidates.Considered a prestigious brand of incrementally modified drugs

Hanmi's Rolvedon set to post $10 mn in Q4 net sales in US

Hanmi's Rolvedon set to post $10 mn in Q4 net sales in US

Rolvedon, a neutropenia agent developed by Hanmi Pharmaceutical South Korean drugmaker Hanmi Pharmaceutical Co.’s neutropenia agent, Rolvedon (eflapegrastim-xnst), is forecast to achieve about $10 million in net sales in the US for the fourth quarter of 2022.Spectrum Pharmaceuticals, Hanm

Spectrum to push back launch date of Hanmi-developed drug Poziotinib

Spectrum to push back launch date of Hanmi-developed drug Poziotinib

An aerial view of Hanmi Pharmaceutical's headquarters  Hanmi Pharmaceutical Co. announced Friday that California-based Spectrum Pharmaceuticals Inc. received a Complete Response Letter (CRL) from the US Food and Drug Administration (FDA), which will delay a new drug’s release date.&n

Hanmi’s anti-cancer drug Rolontis gets FDA approval; US sale via Spectrum

Hanmi’s anti-cancer drug Rolontis gets FDA approval; US sale via Spectrum

Rolontis, a neutropenia agent, will be sold in the US under the Rolvedon brand South Korea’s Hanmi Pharmaceutical Co. said on Tuesday that Rolontis, an anti-cancer drug it has jointly developed with its US partner, has obtained marketing approval from the US Food and Drug Administration.T

FDA to review Hanmi Pharmaceutical’s Rolontis for marketing approval

FDA to review Hanmi Pharmaceutical’s Rolontis for marketing approval

Rolontis, a neutropenia agent developed by Hanmi Pharmaceutical The US Food and Drug Administration has begun reviewing a medicine developed by South Korea’s Hanmi Pharmaceutical Co. for marketing authorization of the white blood cell disease treatment.The FDA will complete its review of

(* comment hide *}